<DOC>
	<DOCNO>NCT01705990</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability immunogenicity Sendai HIV vaccine SeV-G ( NP ) give intranasally Ad35-GRIN administer intramuscularly prime-boost regimen HIV-uninfected , healthy adult volunteer .</brief_summary>
	<brief_title>Safety Immunogenicity Study SeV-G ( NP ) HIV Vaccine Administered Intranasally Ad35-GRIN HIV Vaccine Given Intramuscularly Prime-Boost Regimens HIV-Uninfected Volunteers</brief_title>
	<detailed_description>The study randomize , double-blind , placebo-controlled , dose-escalation trial assess safety , tolerability , immunogenicity SeV-G ( NP ) give intranasally drops Ad35-GRIN administer intramuscularly four prime-boost regimen . Volunteers screen 42 day 1st vaccination follow 12 month last vaccine administration ( 16 month first vaccination ) . It anticipate take approximately 6 month enroll study . Approximately 64 volunteer ( 48 vaccine 16 placebo recipient ) include study .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>healthy male female adult , 18 50 year age ( 21 50 year age volunteer Rwanda ) , report highrisk behaviour HIV infection , available duration trial , willing undergo HIV testing , use effective method contraception , , opinion principal investigator designee , understand study provide write informed consent . confirm HIV infection , pregnancy lactation , significant acute chronic disease , clinically significant laboratory abnormality , recent vaccination receipt blood product , previous receipt HIV vaccine , previous severe local systemic reaction vaccination history severe allergic reaction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>HIV</keyword>
	<keyword>AIDS</keyword>
	<keyword>HIV vaccine</keyword>
	<keyword>HIV prevention</keyword>
</DOC>